

**ASX RELEASE**

**29 July 2021**

**ASX: NVU**

## **Quarterly Activities Report and Appendix 4C for the Quarter Ended 30 June 2021**

### **Highlights:**

- **Strong sales bolstered by international distributor partners and flagship B2B customers**
- **Record quarterly cash receipts delivered following uptake of Nanoshield antiviral product**
- **Nanoveu to pursue US sales via MoU for EPA approved material**

Nanoveu Limited (“Nanoveu” or the “Company”) is pleased to provide its quarterly cash flow report for the quarter ended 30 June 2021, in which the Company’s sales efforts has delivered record cash receipts from customers.

The strong financial performance has been driven by increased uptake of the Nanoshield antiviral film product, as Nanoveu continues to build its network of international distribution partners as well as flagship customers, including Nestle Professional (see *ASX Announcement dated 25 March 2021*).

### **Commenting on the quarter, Nanoveu Executive Chairman and CEO Alfred Chong said:**

*“We have made a concerted effort to push sales initiative to realise the potential of our Nanoshield film. In doing so, Nanoveu has also strengthened its ties to its international network of customers and distributors. The returns have delivered record quarterly revenues, but also feedback that has allowed us to broaden the range of Nanoshield films. Having developed and commercialised the antiviral product, we are set to build scale through our distribution partners and direct customers.*

*“Nanoveu now has a substantial pipeline of opportunities that have assisted us in this successful quarter and also sees us in good stead entering into the new financial year.”*

During the period, Nanoveu also signed a memorandum of understanding (MoU) for the twelve-month non-exclusive supply of copper iodide metal powder or “Cupron Enhanced Product” (CEP) for use in Nanoshield antiviral and antimicrobial products sold in the USA (see *ASX Announcement dated 6 May 2021*).

CEP material is registered under the United States Environmental Protection Agency (EPA). The agreement allows Nanoveu to sell its Nanoshield product (using CEP) under Cupron’s EPA Registration.

Cupron is a respected supplier of copper-based antimicrobial solutions focused on the healthcare market. Their EPA registrations enable us to fulfil the stringent criteria set by the EPA, for our efficacy claims and using CEP, are able to make claims, including the provision of antimicrobial protection, prevention of bacteria, fungi, mould and mildew growth, and the ability to keep surfaces cleaner for longer periods.

For personal use only

Cupron will also endeavour to receive approval from the EPA for a new Public Health Claim – relating to antiviral properties – based on Cupron’s existing EPA Registration.

The supplier’s technology has been developed over a period of decades and is now used in a number of medical textile settings, such as antimicrobial hospital bed linen.

Cupron’s patented and proprietary embedded copper technology has earned multiple, unique public health claims from the US Environmental Protection Agency, and additional innovations are in development.

### **Indian Distributor Update**

During the period, Nanoveu executed an exclusive distribution agreement covering the market of India with Mumbai-based group Verstech (*see ASX Announcement dated 27 April 2021*).

As part of the signed agreement, Verstech offered commitments for prepaid purchase orders to be fulfilled within the first 90 days of the agreement. However, despite the agreement remaining within the 90-day period Nanoveu is yet to receive confirmed orders from the distributor. Verstech has cited delays due to rolling lockdowns in India shortly after the signing of the agreement, as well as an ongoing disrupted supply chain. While unfortunate, Nanoveu continues to engage with Verstech with the hopes of receiving orders. Nanoveu retains its right to terminate the agreement should the distributor not provide a satisfactory outcome. Despite delays in the Indian market, the Company continues to deliver growing sales which it anticipates to be strengthened with potential expansion into the Indian market in the future.

### **Efficacy testing**

Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses. Post quarter-end, the Nanoshield product was determined to be effective against SARS-CoV-2 (COVID-19) in a study completed by researchers from Nestlé Research, Institute of Food Safety and published in the Applied and Environmental Microbiology journal<sup>1</sup>. Nanoshield was determined to eliminate 99.99% of COVID-19 at time-stamp ‘0’ (15 minutes drying/contact time) and remained effective after repeated cleaning and frequent touching.

The antiviral protection has also been validated against a range of other bacteria and viruses including OC43 (eliminating up to 99.99%<sup>2</sup>), E.coli, Influenza A (subtype H3N2), and coronavirus MHV-A59<sup>3</sup>. Additionally, testing simulating 12 months outside weather conditions has found Nanoveu’s products retain their effectiveness against MS2 Bacteriophage, a single-strand RNA virus<sup>4</sup>.

### **Corporate**

The Company held its Annual General Meeting on 2 July 2021. All resolutions were passed.

#### *Expenditure:*

An Appendix 4C detailing expenditure for the quarter is appended. Payments to related parties totalling \$124k were paid during the quarter for directors’ fees, executive remuneration, and pension / superannuation benefits.

Advertising and marketing costs of \$72k and production costs of \$150k were paid in relation to the Company’s anti-viral products.

<sup>1</sup> See announcement of 28 July 2021

<sup>2</sup> See announcements of 5 and 25 May 2020

<sup>3</sup> See announcement of 15 April 2020

<sup>4</sup> See ASX announcement of 18 February 2021

- Ends -

This announcement has been authorised for release by Nanoveu's Executive Chairman and CEO.

**For further information, please contact:**

**Alfred Chong**  
**Executive Chairman and CEO**

t: +65 6557 0155  
e: info@nanoveu.com

**For media / investor enquiries, please contact:**

**David Tasker / Alex Baker**  
**Chapter One Advisors**

t: + 61 433 112 936 / +61 432 801 745  
e: dtasker@chapteroneadvisors.com.au

**About Nanoveu:**

Nanoveu is a technology company developing a range of products for mobile phones and other digital displays. The Company's wholly-owned, flagship product is its Nanoshield antiviral protection which is available in a variety of mobile phone screen covers, mobile phone cases and as a commercial film capable of being applied to a number of surfaces. The product is a clear plastic containing a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. The product is commercially available and sold in a number of countries via Nanoveu's channel partners. Nanoveu also produces EyeFly3D™, which converts 2D digital displays into 3D without the need for 3D glasses and is currently available for Apple iPhones and Google Pixel 3 phones.

In addition, the Company is also developing the following products:

- Customskins: vending machines capable of precisely applying screen covers to mobile phones in just over a minute and with an alignment accuracy of 150 microns;
- EyeFyx: a vision correction solution under development using hardware and software to manipulate screen output; and
- Anti-reflective coating technology capable of being applied to mobile phones, tablets, automotive displays and other digital displays.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Nanoveu Limited

**ABN**

97 624 421 085

**Quarter ended ("current quarter")**

30 June 2021

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	206	305
1.2 Payments for		
(a) research and development	(45)	(84)
(b) product manufacturing and operating costs	(150)	(311)
(c) advertising and marketing	(72)	(181)
(d) leased assets	-	-
(e) staff costs	(354)	(706)
(f) administration and corporate costs	(104)	(145)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	22	50
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(497)</b>	<b>(1,072)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(2)	(9)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(2)</b>	<b>(9)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1)	(1)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material) – funds received in advance of the issue of shares as part of a facility of up to \$2.4m	161	761
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>160</b>	<b>760</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,166	1,148
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(497)	(1,072)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(9)

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	160	760
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>827</b>	<b>827</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	163	143
5.2	Call deposits	664	1,024
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>827</b>	<b>1,167</b>

**6. Payments to related parties of the entity and their associates**

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter  
\$A'000**

124

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	2,400	1,200
7.4 <b>Total financing facilities</b>	2,400	1,200

7.5 **Unused financing facilities available at quarter end** 1,200

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The Company has received \$1,200,000 for subscription for shares with the value of \$658,500 to be issued by 3 February 2022, including \$600,000 for subscription for shares with the value of \$658,500 which was approved by shareholders on 28 October 2020.

An additional \$400,000 subscription for shares with the value of \$439,000 to be made (at the investor's election) no later than 3 August 2021 was approved by shareholders on 28 October 2020.

An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription. Nanoveu has not agreed to issue any shares under this additional subscription and both parties may elect to mutually enter into this additional subscription at a future date. There is no obligation on Nanoveu to further enter into this additional subscription.

Each of these investments will be made by way of the Investor prepaying for Placement Shares. The Placement Shares in relation to all or part of each of the above investments will be issued upon the Investor's written request, within 18 months of the final subscription. The number of Placement Shares to be issued is to be determined by applying to the subscription amount prepaid by the Investor, with the Purchase Price equal to the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) during the 20 consecutive actual trading days immediately prior to the relevant Settlement Notice Date. Each issue of Placement Shares must be for no less than \$150,000 of the Placement Shares. The selection of the 5 days within the 20 trading days is at the discretion of the Investor.

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	(497)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	827
8.3 Unused finance facilities available at quarter end (Item 7.5)	1,200
8.4 Total available funding (Item 8.2 + Item 8.3)	2,027
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	4.1

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

- Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

29 July 2021

Date: .....

Executive Chairman and CEO

Authorised by: .....  
(Name of body or officer authorising release – see note 4)

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.